Search
Hydrogenated soybean oil
go.drugbank.com/drugs/DB11302ApprovedLinolenic acid and stearic acids are contained in hydrogenated soybean oil, but hydrogenation results in reduced unsaturation in linolenic acid. … According to the FDA, hydrogenated soybean oil is generally recognized as safe (GRAS) food substance.
Sonrotoclax
go.drugbank.com/drugs/DB18753ApprovedInvestigationalIt promotes tumor cell survival by sequestering proapoptotic proteins and blocking the intrinsic mitochondrial apoptotic pathway. … [A275521,A275522] On May 13, 2026, the FDA granted accelerated approval to sonrotoclax for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two prior
Synonyms: N-[4-({[(1r,4r)-4-hydroxy-4-methylcyclohexyl]methyl}amino)-3- nitrobenzene-1-sulfonyl]-4-(2-{(2S)-2-[2-(propan-2-yl)phenyl]pyrrolidin- 1-yl}-7-azaspiro[3.5]nonan-7-yl)-2-[(1H-pyrrolo[2,3-b]pyridin-5- ylChlortetracycline
go.drugbank.com/drugs/DB09093ApprovedVet approvedWithdrawnIt was discovered in 1945 by the scientist, Benjamin Minge Duggar, working at Lederle Laboratories under the supervision of Yellapragada Subbarow. … The organism was named _Streptomyces aureofaciens_ due to its gold-hued color.
Borage oil
go.drugbank.com/drugs/DB11238ApprovedGLA, which accounts for approximately 24% of the oil, is converted to dihomo-γ-linolenic acid (DGLA) which acts as a precursor to anti-inflammatory mediators such as 1-series prostaglandins and the 3-series … disorders including eczema, seborrheic dermatitis, and neurodermatitis as well as other inflammatory, cardiovascular and endocrine disorders, although its clinical efficacy and long-term effects are not
Mixtures: Cheon Shim Bo HwaHexamethonium
go.drugbank.com/drugs/DB08960ExperimentalIt has been used for a variety of therapeutic purposes including hypertension but, like the other ganglionic blockers, it has been replaced by more specific drugs for most purposes, although it is widely … A nicotinic cholinergic antagonist often referred to as the prototypical ganglionic blocker. It is poorly absorbed from the gastrointestinal tract and does not cross the blood-brain barrier.
Synonyms: N,N,N,N',N',N'-hexamethylhexane-1,6-diaminiumAtacicept
go.drugbank.com/drugs/DB06399ApprovedInvestigational[L63797] The US FDA granted accelerated approval to atacicept-vymj on July 7, 2026, to reduce proteinuria in adults with primary IgA nephropathy at risk for disease progression. … Atacicept is a recombinant fusion glycoprotein that joins the ligand-binding portion of the human TACI receptor to a modified IgG1 Fc domain, allowing it to bind and neutralize two cytokines: B cell activating
Fecal microbiota
go.drugbank.com/drugs/DB17743ApprovedInvestigational[A259172] REBYOTA, a live fecal microbiota suspension for rectal use, was approved by the FDA in November 2022. … For this type of therapy to be efficient, qualified donors must be selected.
Revakinagene taroretcel
go.drugbank.com/drugs/DB05344ApprovedInvestigational[L52270] Revakinagene taroretcel delivers CNTF to the retina to lower the extent of neuroregeneration. … [A265115] On March 6, 2025, FDA approved revakinagene taroretcel for the treatment of idiopathic macular telangiectasia type 2.
Bilastine
go.drugbank.com/drugs/DB11591ApprovedBilastine is a novel new-generation antihistamine that is highly selective for the H1 histamine receptor, has a rapid onset and prolonged duration of action.
Categories: Histamine H1 Antagonists, Non-SedatingErlotinib
go.drugbank.com/drugs/DB00530ApprovedInvestigationalErlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer … Erlotinib binds to the epidermal growth factor receptor (EGFR) tyrosine kinase in a reversible fashion at the adenosine triphosphate (ATP) binding site of the receptor.